The Board of Directors of the Company at their meeting held today i.e. November 13, 2025, have inter alia, approved and took on record the Unaudited Standalone Financial Results for the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 1.2 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vaxfab Enterprises' Board, at its meeting on November 13, 2025, approved the unaudited standalone financial results for the quarter and half year ended September 30, 2025, along with a clean (unmodified) limited review report from auditors S S R V & Associates. Revenue from operations surged to ₹5,504 lakhs in Q2 FY26 from just ₹1,067 lakhs in Q2 FY25, and to ₹6,961 lakhs for H1 FY26 (vs ₹1,067 lakhs in H1 FY25), reflecting very strong top-line growth. Despite this, the company remained in the red with a Q2 loss of ₹225 lakhs and an H1 loss of ₹186 lakhs, though losses narrowed sharply from ₹764 lakhs in H1 FY25. On the balance sheet, trade receivables ballooned to ₹8,238 lakhs (from ₹2,117 lakhs) while inventories plunged to just ₹9 lakhs (from ₹6,627 lakhs), suggesting significant stock liquidation. Operating cash flow turned positive at ₹78 lakhs, and cash balances improved to ₹122 lakhs.
Investors should note the dramatic revenue jump is encouraging, but persistent losses and a sharp rise in trade receivables relative to revenue warrant close watch on collection quality. The narrowing losses and positive operating cash flow are positive signs, though the stock remains loss-making at the bottom line.